sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interests and short positions in Avadel Pharmaceuticals plc. According to Form 8.3, filed under the Irish Takeover Panel rules, Vanguard holds 5,787,867 ordinary shares, representing a 5.94% interest in the company. This disclosure comes as of January 29, 2026.
The filing states no additional dealings beyond these equity interests, and no cash-settled or stock-settled derivatives have been reported. Furthermore, there are no indemnity or other agreements related to securities of Avadel Pharmaceuticals linked to this disclosure.
This transparency is part of the regulatory requirements under the Irish Takeover Panel Act of 1997, ensuring that significant shareholders disclose their positions for market integrity and investor awareness.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.